OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.